Cytek Biosciences, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Glenn P. Muir

Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Glenn P. Muir”): 79,599,103 for, 5,894,350 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following res…”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 32,417,672 for, 801,219 withheld, 2,017,909 abstained.

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

Description as filed by funds: To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Ming Yan, Ph.D.

Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Ming Yan, Ph.D.”): 76,741,063 for, 8,752,390 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following res…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 31,527,416 for, 1,663,325 withheld, 2,046,059 abstained.

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

Description as filed by funds: To elect our three Class II director nominees, Vera Imper, Ph.D., Glenn P. Muir, and Ming Yan, Ph.D., each to serve a three-year term expiring at our 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal: Vera Imper, Ph.D.

Cytek Biosciences, Inc.’s own tally for this item (“Elect Director: Vera Imper, Ph.D.”): 64,769,976 for, 20,723,477 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class II director, to hold office until the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal, based on the following res…”
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 28,289,297 for, 4,625,628 withheld, 2,321,875 abstained.

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers for the year ended December 31, 2025, as set forth in our proxy statement.

Cytek Biosciences, Inc.’s own tally for this item (“2. Executive Compensation. On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2025”): 84,794,380 for, 677,861 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “On a non-binding, advisory basis, the compensation paid to the Company's named executive officers for the year ended December 31, 2025 was approved based on the following results of voting:”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 58 managers: 35,082,545 for, 281,582 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 138 managers: 41,060,280 for, 494,797 against, 11,449 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Cytek Biosciences, Inc.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm. The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December”): 110,533,253 for, 479,883 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 35,242,668 for, 2,641 against.

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.